Glenmark Pharmaceuticals Ltd. and its subsidiary, Ichnos Sciences Inc., have announced the launch of their alliance, Ichnos Glenmark Innovation (IGI), to accelerate new drug discovery in cancer treatment. This alliance combines Glenmark’s research and development proficiencies in small molecules with those of Ichnos in novel biologics to continue developing cutting-edge therapy solutions that treat hematological malignancies and solid tumors.
IGI features a robust pipeline of three innovative oncology molecules targeting multiple myeloma, acute myeloid leukemia and solid tumors currently undergoing clinical trials. Two of these molecules have received orphan drug designation from the USFDA. Additionally, IGI has two autoimmune disease assets that have been out-licensed to leading companies.
With over 150 scientists, IGI is utilizing three global centers: Ichnos’ clinical development headquarters in New York City, a biologics research center in Lausanne, Switzerland, and Glenmark’s small molecule research center in Mumbai, India.